Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report January – September 2020

High growth and good profitabilityJuly – September 2020 · Net sales increased by 16.1 percent to SEK 1,643 (1,416) million. Organic growth, adjusted for currency effects, was -2.7 (14.6) percent. · EBIT increased to SEK 140 (113) million, which corresponds to an EBIT margin of 8.5 (8.0) percent. · Cash flow from operating activities for the period was SEK 90 (114) million. · Six acquisitions were made during the quarter, which on an annual basis contribute an estimated total sales of SEK 496 million. · Earnings per share for the period amounted to SEK 2.01 (1.59).

Olvi plc: Notification of Manager’s Transactions

Olvi plc                Stock Exchange Release 9 NOV 2020 AT 12.00 pm Olvi plc: Notification of Manager’s Transactions Person subject to the notification requirementName: Akkel, PeepPosition: Other senior managerIssuerName: Olvi plcLEI: 7437003NX7WWVRT6AJ55Initial notificationReference number: 7437003NX7WWVRT6AJ55_20201106195011_2 Transaction detailsTransaction date: 5.11.2020Venue: NASDAQ HELSINKI LTD (XHEL)Nature of transaction: DISPOSALInstrument: ShareISIN: FI0009900401 Volume: 200Unit price: 47.20000Aggregated transactions:Volume: 200

Sweden’s first testbed for sustainable composite manufacturing

In Piteå, Northern Sweden, the Swedish research institute RISE, is building an innovative facility for testingsustainable composite manufacturing. The testbed for sustainable composite manufacturingat RISE  offers new opportunities for testing, developing and demonstrating sustainable material, technologies and manufacturing processes for the future. The heart of the test bed is a servohydraulic press from AP&T.Set to be inaugurated in April, the testbed will give researchers and companies far more opportunities for testing, developing and demonstrating sustainable material, technologies

Ericsson and Telstra collaborate on edge cloud for enterprises

· Following a successful 5G edge computing trial with an Australian financial institution in 2019, Ericsson and Telstra are now developing an enterprise solution with an extension into the hybrid cloud space · This collaboration will serve as a catalyst for further innovation, unlocking new potential enterprise use cases in sectors such as agriculture, industrial IoT, enterprise branch services and smart cities.Ericsson (NASDAQ: ERIC) and Telstra have announced they will collaborate to develop an enterprise edge cloud solution developed specifically for the Telstra domain. This

CXO, Lars Andersson, leaves Lime Technologies

Lars Andersson will leave Lime Technologies at the end of January, 2021. He has been a vital part of Lime Technologies' growth journey for many years, most recently as responsible for IR, market and product.- In recent years, Lars has built a reputable brand and driven a successful transformation of Lime's product portfolio. With the transformation work completed and product and market organizations that are strong, he now chooses to leave for new challenges. Lars will be available if necessary during the spring, as the work to recruit his replacement is carried out. Lars has been a very

Neste Corporation - Managers' Transactions, Lehmus (disposal)

Neste Corporation, Managers' Transactions, 9 November 2020 at 11 a.m. (EET)____________________________________________Person subject to the notification requirementName: Lehmus, MattiPosition: Other senior managerIssuer: Neste OyjLEI: 5493009GY1X8GQ66AM14Notification type: INITIAL NOTIFICATIONReference number: 5493009GY1X8GQ66AM14_20201109100326_3____________________________________________Transaction date: 2020-11-06Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009013296Nature of the transaction: DISPOSALTransaction details(1): Volume: 467

SKF and Imperial College London pushing the limits of tribology-related bearing R&D

SKF and Imperial College London, with over 190 years of combined experience in tribology research, extend relationship for a further five years.Gothenburg, Sweden, 9 November 2020: SKF, founded in 1907 and Imperial College London, involved in tribology research since 1948, are extending their R&D partnership. The SKF University Technology Centre (UTC) has been housed at Imperial College London since 2010 and has delivered research that helps bearings perform better and longer, whilst also contributing to lower energy consumption in the machines they operate in. This work will now continue

Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial

On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy (IgAN). Calliditas will host a telephone conference with a presentation of the topline results today at 2:30 pm CET. The event will be hosted by the company’s CEO, Renée Aguiar-Lucander and CMO, Richard Philipson. The presentation will be held in English. The presentation will be live on the company’s website during the call under Financial Reports and Presentations

Kemira Oyj: Announcement of manager’s transaction; Chairman of the Board Jari Paasikivi has purchased 7,500 Kemira shares

Kemira Oyj, Managers' transactions, November 9, 2020 at 11.00 am (EET) Kemira Oyj: Announcement of manager’s transaction; Chairman of the Board Jari Paasikivi has purchased 7,500 Kemira shares  Kemira has received a notification from Jari Paasikivi, Chairman of the Board, of a transaction made with its financial instrument, according to the EU Market Abuse Regulation. Detailed information about the transaction is given below. Person subject to the notification requirement:Name: Paasikivi, JariPosition: Chairman of the BoardIssuer: KEMIRALEI: 74370031Y7RK5H88CQ48

Dampskibsselskabet NORDEN A/S – Weekly report on share buy-back

ANNOUNCEMENT NO. 89 - 9 NOVEMBER 2020 On 4 November 2020, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 4 November 2020 up to and including no later than end February 2021. For details please see announcement no. 87 of 4 November 2020. Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 20 million (approximately DKK 126 million).

Extraordinary General Meeting in Concentric

The Concentric AB board of directors has resolved to convene an Extraordinary General Meeting to be held on Wednesday, December 9, 2020. Further details regarding the proposals for the meeting can be found in the notice, which is presented in its entirety below. The notice is expected to be published in the Swedish Official Gazette (Post- och Inrikes Tidningar) and on the company’s website within the next few days. Unofficial English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take

Stronger together with new branding – The new era of Glaston seeing it through

GLASTON CORPORATION    PRESS RELEASE           9.11.2020Glaston is launching its new brand to communicate the full strength of the new Glaston. Glaston has now strengthened its commitment to being the innovative technology leader and enabling its customers to realize their highest ambitions in glass. This means Glaston is delivering on its promise of enabling to build a better tomorrow through safer, smarter and more energy-efficient glass solutions. The new Glaston brand now better captures the broader, more versatile offerings after the acquisition of Bystronic glass in 2019. “We’re

MAG Interactive celebrates its ten-year anniversary with festive game events and nominates Player of the Decade

MAG Interactive celebrates its tenth year by launching special events in six of its games where players can compete to become the MAG player of the decade.Stockholm, Sweden - November 9, 2020 - 2020 MAG Interactive celebrates its tenth year as a company and launches special events in six of its games: New QuizDuel, Wordzee, Word Domination, Ruzzle, WordBrain and WordBrain 2. MAG also announces a unique competition: Players participating in at least five of these exclusive ten-year events compete to be crowned the MAG “Player of the Decade”. In addition to this honorary title, the winner

CELLINK will help develop 3D bioprinted personalised scaffolds for tissue regeneration of ankle joint s as part of the TRIANKLE project

The TRIANKLE consortium – made up of 12 European organisations, will develop 3D bioprinted personalised scaffolds for tissue regeneration of ankle joints. This ambitious research project in regenerative medicine has an overall budget of €5.9M and will be developed over 4 years, starting January 2021. CELLINK´s portion of the grant is. €622,000 of which EU accounts for 100 percent of the costs. The consortium aims to create innovative personalised collagen- and gelatine-based implants manufactured with 3D technology for patients with tendinopathies such as Achilles tendon partial ruptures

iLOQ products are available from 1,000 retailers around the world

Finnish digital locking company, iLOQ, is growing rapidly. The Company's access management solutions are now available in 1,000 locations in nearly 30 countries around the world. iLOQ was founded in 2003. In 2007, iLOQ introduced the world's first battery-free digital locking system that harvests energy for unlocking from the motion of pushing the key into the lock. In 2016, iLOQ released the first lock cylinder that generates the electrical power it needs for unlocking from an NFC-compatible smartphone.iLOQ employs more than 170 people. It currently has sales offices in Sweden,

Salipro Biotech and DyNAbind enter collaboration agreement

Stockholm, Sweden / Dresden, Germany, 09 November 2020 – Salipro Biotech AB and DyNAbind GmbH are teaming up to tackle drug discovery against challenging membrane protein targets! By bringing together Salipro’s proprietary membrane stabilizing platform technology with DyNAbind’s proprietary DNA-Encoded Library (DEL) technologies, the teams aim to accelerate the development of novel drugs for these contemporary targets. Jens Frauenfeld, co-founder and CEO of Salipro Biotech AB: “We are excited to develop novel hits for challenging drug targets such as GPCR and Ion Channels with DyNAbind.

Aker Solutions ASA: Update on Contemplated Merger With Kværner ASA

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. November 9, 2020 - Reference is made to the previous stock exchange announcements made by Aker Solutions ASA (“Aker Solutions”) regarding the contemplated merger with Kværner ASA (“Kvaerner”) as further set out in the merger plan dated July 17, 2020

Subscription period for Subsequent Offering ends today

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. Reference is made to the stock exchange notice by Solstad Offshore ASA (the "Company") on 26 October 2020 regarding the commencement of the subscription period for the subsequent offering of 1,336,973 new shares, each with a par value of NOK 1.00 (

Grant of Options subject to shareholder approval - Mandatory notification of options and shareholding

Reference is made to announcement on 1. November regarding grant of options, subject to shareholder approval, in Otello Corporation. The strike price has been determined based on the volume weighed averaged trading price the Company's shares 5 trading days after the date of grant (2. November – 6. November). The strike price is determined to be 18.99kr.   Petter Lade, CFO Phone: +47 91143878 E-mail: petterl@otellocorp.com   About Otello: Otello holds shares in several different businesses, including (i) AdColony which helps publishers monetize their content through

First hospital in unique digital pathology network in UK now live with Sectra’s solution

Linköping, Sweden – November 9, 2020 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) has deployed its software for medical imaging at Leeds Teaching Hospitals. It is the first of an initial six trusts in the Northern Pathology Imaging Co-operative (NPIC) to go live, paving the way for one of the most sophisticated interconnected pathology initiatives in the world. The technology from Sectra will underpin the regional program that is digitizing, connecting and applying artificial intelligence to pathology services in the North of

Interim Report Q3 - July - September, 2020 Redsense Medical AB (publ)

FINANCIAL SUMMARY Third quarter, 1 July – 30 September 2020 The Redsense Group · Net sales amounted to KSEK 2,107 (4,645), a 55 percent decrease compared with the corresponding period in 2019. · Profit or loss before tax amounted to KSEK -3,723 (-590). The Swedish Parent Company · Net sales amounted to KSEK 1,595 (3,257). · Profit or loss before tax amounted to KSEK -3,170 (-895). 1 January – 30 September 2020 The Redsense Group · Net sales amounted to KSEK 12,213 (9,439), a 29 percent increase compared with the corresponding period in 2019. · Profit

Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia

9 November 2020 07:00 GMT Calquence approved in the EU for thetreatment of chronic lymphocytic leukaemia Calquence demonstrated superior progression-free survival and favourable tolerability in both previously untreated and relapsed or refractory patients AstraZeneca's Calquence (acalabrutinib), a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. The approval by the European Commission was

There are no items matching the current filter
There are no more items matching the current filter
Back to top